Guangdong Kanghua Healthcare Group Co (FRA:E9Q) Research & Development: €0.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:E9Q Guangdong Kanghua Healthcare Group Co Ltd FRA:E9Q
84 GF Score
Price €0.17
GF Value €0.20
! 1 Warning Sign
View Full Analysis

What is Guangdong Kanghua Healthcare Group Co Research & Development?

Guangdong Kanghua Healthcare Group Co FRA:E9Q +1.17% 84 Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus rates FRA:E9Q with a GF Score™ of 84/100 and a GF Value™ of €0.20. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Guangdong Kanghua Healthcare Group Co's Research & Development for the six months ended in Dec. 2025 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.0 Mil.

Guangdong Kanghua Healthcare Group Co  (FRA:E9Q) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Guangdong Kanghua Healthcare Group Co Research & Development Related Terms

Guangdong Kanghua Healthcare Group Co Research & Development Historical Data

* Premium members only.

The historical data trend for Guangdong Kanghua Healthcare Group Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangdong Kanghua Healthcare Group Co Research & Development Chart

Guangdong Kanghua Healthcare Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Guangdong Kanghua Healthcare Group Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:E9Q
84GF Score
Guangdong Kanghua Healthcare Group Co Ltd FRA:E9Q
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guangdong Kanghua Healthcare Group Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
Guangdong Kanghua Healthcare Group Co (FRA:E9Q) has a Research & Development of €0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Guangdong Kanghua Healthcare Group Co and its competitors.
Is Guangdong Kanghua Healthcare Group Co's Research & Development too high?
Guangdong Kanghua Healthcare Group Co's current Research & Development is €0.0 Mil. Overall, Guangdong Kanghua Healthcare Group Co has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Guangdong Kanghua Healthcare Group Co's Research & Development compare to HCA and THC?
Guangdong Kanghua Healthcare Group Co's Research & Development of €0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Guangdong Kanghua Healthcare Group Co and its competitors. Guangdong Kanghua Healthcare Group Co's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangdong Kanghua Healthcare Group Co stock overvalued right now?
Guangdong Kanghua Healthcare Group Co (FRA:E9Q) has a current Research & Development of €0.0 Mil. The stock's GF Value™ is €0.20, compared to a current price of €0.17 — trading 13.5% below its estimated fair value. The current Research & Development is €0.0 Mil. Guangdong Kanghua Healthcare Group Co's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Guangdong Kanghua Healthcare Group Co (FRA:E9Q), the current Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guangdong Kanghua Healthcare Group Co (FRA:E9Q) Overvalued in 2026?

Based on GuruFocus' analysis, Guangdong Kanghua Healthcare Group Co stock appears to be undervalued. The current stock price of €0.17 is trading 13.5% below its estimated GF Value™ of €0.20.

Key valuation signals for FRA:E9Q:

  • Research & Development: €0.0 Mil
  • GF Value™: €0.20 vs. price of €0.17 (13.5% below fair value)
  • GF Score™: 84/100 with 1 warning sign

No single metric tells the full story. See the FRA:E9Q stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guangdong Kanghua Healthcare Group Co Business Description

Other Exchanges 03689:Hong Kong
Address 1000 Dongguan Avenue, Guangdong Province, Dongguan, CHN
Guangdong Kanghua Healthcare Group Co Ltd provides healthcare services. The reportable segments are as follows, The Hospital services segment, which generates majority revenue, includes the provision of hospital services including inpatient healthcare services, outpatient healthcare services, and physical examination services; Rehabilitation and other healthcare services including the provision of rehabilitation services; Elderly healthcare services include the provision of elderly healthcare services, including assisted living, adult daycare, longterm care, residential care and hospice care to the aged patients; and Haemodialysis services segment is principally engaged in the operation of haemodialysis outpatient centres. It generates all of its revenue from the PRC.
84GF Score

Get the complete analysis for FRA:E9Q

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.17
Price
€0.20
GF Value